VNDA Quote, Financials, Valuation and Earnings

CytomX Therapeutics has a net margin of -11.17% compared to Vanda Pharmaceuticals's net margin of 17.16%. Vanda Pharmaceuticals's return on equity of -3.02% beat CytomX Therapeutics's return on equity of --.

Vanda Pharmaceuticals has a consensus price target of $12.17, signalling upside risk potential of 168.58%. On the other hand CytomX Therapeutics has an analysts' consensus of $4.69 which suggests that it could grow by 428.06%. Given that CytomX Therapeutics has higher upside potential than Vanda Pharmaceuticals, analysts believe CytomX Therapeutics is more attractive than Vanda Pharmaceuticals.

Vanda Pharmaceuticals has a beta of 0.766, which suggesting that the stock is 23.396% less volatile than S&P 500. In comparison CytomX Therapeutics has a beta of 1.030, suggesting its more volatile than the S&P 500 by 2.991%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytomX Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. CytomX Therapeutics pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $47.7M, which are larger than CytomX Therapeutics quarterly revenues of $33.4M. Vanda Pharmaceuticals's net income of -$5.3M is lower than CytomX Therapeutics's net income of $5.7M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while CytomX Therapeutics's PE ratio is 5.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.38x versus 0.59x for CytomX Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -11.17% compared to Vanda Pharmaceuticals's net margin of 11.99%. Vanda Pharmaceuticals's return on equity of -3.02% beat Johnson & Johnson's return on equity of 20.88%.

Vanda Pharmaceuticals has a consensus price target of $12.17, signalling upside risk potential of 168.58%. On the other hand Johnson & Johnson has an analysts' consensus of $171.61 which suggests that it could grow by 18.79%. Given that Vanda Pharmaceuticals has higher upside potential than Johnson & Johnson, analysts believe Vanda Pharmaceuticals is more attractive than Johnson & Johnson.

Vanda Pharmaceuticals has a beta of 0.766, which suggesting that the stock is 23.396% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.514, suggesting its less volatile than the S&P 500 by 48.607%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.4% to investors and pays a quarterly dividend of $1.24 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vanda Pharmaceuticals quarterly revenues are $47.7M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Vanda Pharmaceuticals's net income of -$5.3M is lower than Johnson & Johnson's net income of $2.7B. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 23.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.38x versus 4.00x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Kodiak Sciences has a net margin of -11.17% compared to Vanda Pharmaceuticals's net margin of --. Vanda Pharmaceuticals's return on equity of -3.02% beat Kodiak Sciences's return on equity of --.

Vanda Pharmaceuticals has a consensus price target of $12.17, signalling upside risk potential of 168.58%. On the other hand Kodiak Sciences has an analysts' consensus of $6.67 which suggests that it could fall by -14.64%. Given that Vanda Pharmaceuticals has higher upside potential than Kodiak Sciences, analysts believe Vanda Pharmaceuticals is more attractive than Kodiak Sciences.

Vanda Pharmaceuticals has a beta of 0.766, which suggesting that the stock is 23.396% less volatile than S&P 500. In comparison Kodiak Sciences has a beta of 2.113, suggesting its more volatile than the S&P 500 by 111.317%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Kodiak Sciences pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $47.7M, which are larger than Kodiak Sciences quarterly revenues of --. Vanda Pharmaceuticals's net income of -$5.3M is higher than Kodiak Sciences's net income of -$43.9M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Kodiak Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.38x versus -- for Kodiak Sciences. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -11.17% compared to Vanda Pharmaceuticals's net margin of -49.65%. Vanda Pharmaceuticals's return on equity of -3.02% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Vanda Pharmaceuticals has a consensus price target of $12.17, signalling upside risk potential of 168.58%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 393.38%. Given that NovaBay Pharmaceuticals has higher upside potential than Vanda Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Vanda Pharmaceuticals.

Vanda Pharmaceuticals has a beta of 0.766, which suggesting that the stock is 23.396% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $47.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Vanda Pharmaceuticals's net income of -$5.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.38x versus 0.08x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.